1 min read
Add as a preferred source on GoogleUltragenyx Pharmaceutical Inc. Agrees to Sell Fayuvi Voucher for $203 Million
The priority review voucher was received in connection with Fayuvi’s approval in September. The therapy is also known as rebisufligene etisparvovec.
Ultragenyx Pharmaceutical Inc. agreed to sell a U.S. Food and Drug Administration (FDA) priority review voucher for $203 million. The voucher was received in connection with the September approval of Fayuvi, a rare disease gene therapy also known as rebisufligene etisparvovec.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.